Difference between revisions of "Isatuximab (Sarclisa)"
Jump to navigation
Jump to search
m (Jwarner moved page Isatuximab (SAR-650984) to Isatuximab (Sarclisa): FDA approval) |
|||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
| − | |||
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Revision as of 02:52, 3 March 2020
General information
Class/mechanism from NCI Drug Dictionary: A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 3/2/2020: Approved in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Also known as
- Code name: SAR-650984
- Generic name: isatuximab-irfc
- Brand name: Sarclisa